0.34 (+5.00%)

POWR Rating

Component Grades













Add PHAT to Watchlist
Sign Up

Industry: Biotech


of 379

in industry

Filter PHAT News Items

PHAT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PHAT News Highlights

  • For PHAT, its 30 day story count is now at 2.
  • Over the past 20 days, the trend for PHAT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest PHAT News From Around the Web

Below are the latest news stories about PHATHOM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PHAT as an investment opportunity.

Here's Why Phathom Pharmaceuticals, Inc. (PHAT) Is a Great 'Buy the Bottom' Stock Now

Phathom Pharmaceuticals, Inc. (PHAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Yahoo | March 27, 2023

All You Need to Know About Phathom Pharmaceuticals, Inc. (PHAT) Rating Upgrade to Buy

Phathom Pharmaceuticals, Inc. (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | March 7, 2023

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Meeting scheduled in March 2023 with the U.S. Food and Drug Administration (FDA) to discuss stability data and resubmission requirements for erosive GERD and H. pylori New Drug Applications FLORHAM PARK, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quarter and full year ended December 31, 202

Yahoo | February 28, 2023

Phathom Pharma Shares Fall After Formal FDA Request For Vonoprazan Data

The FDA has formally asked for additional stability data to demonstrate that levels of the impurity previously found in Phathom Pharmaceuticals Inc's (NASDAQ: PHAT) vonoprazan drug product will remain at or below the daily acceptable intake throughout the proposed shelf life of the product. The FDA cited no additional deficiencies in either letter. In August 2022, Phathom detected trace levels of a nitrosamine in vonoprazan drug product in post-approval testing as we prepared for commercial laun

Yahoo | February 10, 2023

Phathom’s stock falls after receiving FDA letters

MARKET PULSE Shares of Phathom Pharmaceuticals Inc. (PHAT) tumbled about 23% in premarket trading on Friday, the day after the company said it received complete response letters from the Food and Drug Administration related to vonoprazan, which is approved for two indications and had also been submitted to the regulator as a potential treatment for erosive esophagitis.

Yahoo | February 10, 2023

Phathom Pharmaceuticals Provides Regulatory Updates

FLORHAM PARK, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced regulatory updates for its approved products, VOQUEZNA™ TRIPLE PAK™ and VOQUEZNA DUAL PAK™, approved in the U.S. for the treatment of H. pylori infection, and its pending New Drug Application (NDA) for vonoprazan for the treatment of erosive esophagitis. Phathom has

Yahoo | February 9, 2023

Why Shares of Phathom Pharmaceutical Jumped This Week

Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy.

Yahoo | January 28, 2023

Great news for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Insiders acquired stock in large numbers last year

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Yahoo | January 24, 2023

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p<0.0001)Data expected to provide the basis for future regulatory submission for vonoprazan as a daily treatment for patients with NERD, pending completion of 20-week safety extension periodOver 45 million people in the U.S. are estimated to have NERD, the largest subcategory of gastroesophageal reflux disease (GERD)

Yahoo | January 8, 2023

The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax

Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax are included in this Analyst Blog.

Yahoo | January 6, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7508 seconds.